Market News & Trends
Voyager Therapeutics & CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
Voyager Therapeutics, Inc. recently announced a research collaboration with CHDI Foundation, Inc. (CHDI) to advance Voyager’s VY-HTT01 program, an adeno-associated virus (AAV)-mediated gene-silencing therapy for…
Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement
Lonza Houston, Inc. and Massachusetts Eye and Ear have entered into a strategic agreement that provides customers the ability to in-license Anc80 and other Anc-AAVs…
Inovalon & MDLIVE Bring Real-Time Advanced Analytics to Telemedicine Marketplace
Inovalon recently announced a multi-year agreement with MDLIVE, a leading telehealth platform provider, to provide on-demand, real-time patient insights and analytics. The new capability will…
Geron Provides Update on Imetelstat Trials Being Conducted by Janssen
Geron Corporation recently provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews…
Dermira Acquires Option to License Exclusive Rights for up to Three Early Stage Programs from Takeda
Dermira, Inc. recently announced it has entered into an exclusive option and license agreement with Takeda Pharmaceutical Company Limited. Pursuant to the terms of the…
Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products
Amyris, Inc., the industrial bioscience company, recently announced that it has completed a subsequent collaboration agreement with Ginkgo Bioworks, which is expected to be approved…
Voyager Therapeutics Licenses Novel Gene Therapy Capsids From the California Institute of Technology
Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), recently announced a co-exclusive worldwide…
Epizyme Earns $6-Million Milestone Payment From GlaxoSmithKline
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, recently announced it has earned a $6 million milestone payment from GlaxoSmithKline (GSK). The milestone…
Bayer Clinches Monsanto With Improved $66-Billion Bid
German drugs and crop chemicals company Bayer has won over US seeds firm Monsanto with an improved takeover offer of around $66 billion, ending months…
Gerresheimer to Sell Life Science Research Business
In line with its strategy of focusing on packaging and device solutions for pharmaceutical customers, Gerresheimer recently announced that it is to sell its Life…
Dipexium Pharmaceuticals Announces Issuance of Patent
Dipexium Pharmaceuticals, Inc. recently announced that the European Patent Office has issued a new Locilex patent in the European Union (EU). The patent claims are…
Crown Bioscience Launches New Translational Platforms
Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance metabolic disease and oncology research, will be announcing the release…
Capsugel Investing in Enhanced Micronization Capacity & Capabilities
Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, recently announced an expansion of its facility in Quakertown, PA, to meet increasing…
Boost Vaccination Data Encourage Continued Development of Parkinson's Vaccine
AFFiRiS AG recently announced results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE PD01A, an active vaccine against Parkinson's disease…
Fuji Health Science Announces Name Change
Fuji Health Science, Inc. recently announced that as of September 1, 2016, the name of the entity has become Fuji Chemical Industries USA, Inc. to…
Allergan Acquires Gene Therapy Company
Allergan plc recently announced it has acquired substantially all of the assets of RetroSense in an all-cash transaction. Under the terms of the transaction, Allergan…
Niagara University Faculty Present Groundbreaking Research, New Insulin Pill For Diabetes Patients
NIAGARA UNIVERSITY, N.Y. - The need for painful insulin injections by certain diabetes patients may be eliminated with the introduction of a new technique…
Aptar Pharma Announces Development & License Agreement With BD
Aptar Pharma Announces Development & License Agreement With BD Aptar Pharma, a leading drug delivery solutions provider and segment of AptarGroup, Inc.…
Results From Preclinical Research & Phase Ib Study of Biogen’s Investigational Alzheimer’s Disease Treatment Published
Results from preclinical research and PRIME, the Phase Ib study of Biogen’s investigational treatment for early Alzheimer’s disease (AD), aducanumab, were published in a recent…
SteadyMed Announces Completion of Pre-NDA Submission Manufacturing Activities
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
